Myriad Genetics, Inc. (MYGN)
MYGN Stock Price Chart
Explore Myriad Genetics, Inc. interactive price chart. Choose custom timeframes to analyze MYGN price movements and trends.
MYGN Company Profile
Discover essential business fundamentals and corporate details for Myriad Genetics, Inc. (MYGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
6 Oct 1995
Employees
2.73k
Website
https://www.myriad.comCEO
Samraat S Raha
Description
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN Financial Timeline
Browse a chronological timeline of Myriad Genetics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.03, while revenue estimate is $206.03m.
Earnings released on 5 May 2026
EPS came in at -$0.09 falling short of the estimated -$0.06 by -50.00%, while revenue for the quarter reached $200.40m , missing expectations by -1.00%.
Earnings released on 23 Feb 2026
EPS came in at $0.04 surpassing the estimated -$0.02 by +300.00%, while revenue for the quarter reached $209.80m , beating expectations by +1.14%.
Earnings released on 3 Nov 2025
EPS came in at -$0.13 falling short of the estimated -$0.01 by -1.20k%, while revenue for the quarter reached $205.70m , missing expectations by -0.61%.
Earnings released on 5 Aug 2025
EPS came in at $0.05 surpassing the estimated -$0.01 by +600.00%, while revenue for the quarter reached $213.10m , beating expectations by +3.83%.
Earnings released on 6 May 2025
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $195.90m , missing expectations by -7.47%.
Earnings released on 24 Feb 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $210.60m , beating expectations by +0.12%.
Earnings released on 7 Nov 2024
EPS came in at $0.06 surpassing the estimated $0.02 by +215.79%, while revenue for the quarter reached $213.30m , missing expectations by -0.12%.
Earnings released on 6 Aug 2024
EPS came in at $0.05 surpassing the estimated $0.01 by +509.01%, while revenue for the quarter reached $211.50m , beating expectations by +3.20%.
Earnings released on 7 May 2024
EPS came in at -$0.01 surpassing the estimated -$0.11 by +90.91%, while revenue for the quarter reached $202.20m , beating expectations by +4.49%.
Earnings released on 27 Feb 2024
EPS came in at $0.04 surpassing the estimated $0.01 by +214.22%, while revenue for the quarter reached $196.60m , beating expectations by +0.93%.
Earnings released on 6 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.08 by +62.50%, while revenue for the quarter reached $191.90m , missing expectations by -1.10%.
Earnings released on 3 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $183.50m , missing expectations by -1.94%.
Earnings released on 3 May 2023
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%, while revenue for the quarter reached $181.20m , beating expectations by +5.63%.
Earnings released on 28 Feb 2023
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%, while revenue for the quarter reached $177.80m , beating expectations by +4.91%.
Earnings released on 1 Nov 2022
EPS came in at -$0.19 falling short of the estimated -$0.06 by -216.67%, while revenue for the quarter reached $156.40m , missing expectations by -8.04%.
Earnings released on 4 Aug 2022
EPS came in at $0.04 surpassing the estimated $0.01 by +300.00%, while revenue for the quarter reached $179.30m , beating expectations by +4.88%.
Earnings released on 5 May 2022
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $164.90m , beating expectations by +5.25%.
Earnings released on 24 Feb 2022
EPS came in at -$0.02 falling short of the estimated -$0.02 by -14.29%, while revenue for the quarter reached $160.80m , missing expectations by -1.32%.
Earnings released on 2 Nov 2021
EPS came in at -$0.02 falling short of the estimated $0.01 by -300.00%, while revenue for the quarter reached $167.30m , beating expectations by +0.60%.
Earnings released on 3 Aug 2021
EPS came in at $0.12 surpassing the estimated -$0.07 by +271.43%, while revenue for the quarter reached $189.40m , beating expectations by +14.71%.
MYGN Stock Performance
Access detailed MYGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
